Protective Effect of Exercise on Acute High-fat Overfeeding (HFDEXC)
4. juni 2026 oppdatert av: Matthew Barberio, George Washington University
Metabolic flexibility is the ability to switch rapidly from one substrate (i.e.
fuel source) to another (e.g.
fats to carbohydrates) in response to ingested foods.
Worse metabolic flexibility is linked to worse metabolic outcomes, but exercise is thought to be protective against nutrient excess.
We will conduct a standard oral glucose tolerance test (OGTT) to assess insulin resistance and metabolic flexibility.
Participants will be randomized to a 24-hour hypercaloric, high-fat diet (HFD) with and without an exercise bout.
During the hypercaloric HFD, participants will eat extra calories with more calories from fat than normal, which is expected to increase insulin resistance.
After each arm of the high-fat diet, we will repeat the OGTT.
During each OGTT, expired gases will be analyzed noninvasively to determine metablic flexibility.
Insulin resistance will be determined with blood drawn during each OGTT.
By comparing metabolic flexiblity and insulin resistance before and after the normal diet and after the high-fat diet intervention, a better understanding of how insulin resistance affects metabolism and how exercise can be protective will be developed.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
50
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20052
- Milken Institute School of Public Health
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Males or females between the ages of 20 and 40 years
- A body mass index (BMI) of 20.0 - 29.9 kg/m2.
- Low risk for risk of injury or health complications as determined by physical activity readiness questionnaire (PARQ).
Exclusion Criteria:
- Are currently taking any antioxidant supplementation (daily multivitamin not included), prescribed non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics, steroids, or probiotics.
- Are currently taking any medications for management of cholesterol, diabetes, or body weight/obesity, or are undergoing hormone therapy.
- Are unwilling or unable to comply with study procedures, at the discretion of the investigators.
- Are unwilling to have biospecimens (blood and urine) collected and stored (only blood) for future research.
- Pregnant women - A urine pregnancy test will be conducted prior to any testing procedures.
- A history of disordered eating, including anorexia nervosa, bulimia nervosa, binge eating disorder, or avoidant restrictive food intake disorder or deemed high-risk for disordered eating via questionnaire.
- A history of gastrointestinal diseases, such as galactosemia, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), Celiac disease, Crohn's disease, or lactose intolerance.
- Individuals with known allergies to wheat or gluten, milk, soy, tree nuts (e.g., almonds, walnuts, pecans), or peanuts.
- Deemed high risk for food insecurity via the Hunger Vital Sign screener.
- Have followed a ketogenic diet within the last three months or have been told to avoid a high-fat diet by a medical provider for risk of cardiovascular disease.
- Cardiorespiratory fitness (VO2max) below the 30th percentile for age and sex (measured at initial screening visit)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: High Fat Overfeeding
Resting metabolic rate will be used estimate total caloric need.
We will use this estimate to create a daily target calorie intake and target fat intake for the High-Fat Diets (HFD) in the study.
During the high-fat diet, subjects will eat 80% more calories than necessary with at least 65% of the calories coming from fat for one day.
|
Caloric intake 180% of daily caloric need with 65% from fat
|
|
Eksperimentell: High Fat Overfeeding + Exercise
On the day of High Fat Overfeeding (See High Fat Overfeeding arm description), subjects will complete a single bout of exercise.
The duration of exercise will be individualized to ~25% of daily energy needs.The intensity of exercise will be individualized to be at a low intensity in the moderate domain.
Extra foods will be provided to match energy balance across the high-fat overfeeding days
|
Caloric intake 180% of daily caloric need with 65% from fat with acute moderate exercise (energy expenditure ~25% of daily caloric need).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Insulin Sensitivity via Oral Glucose Insulin Sensitivity Index
Tidsramme: Immediately following high fat diet intervention
|
Oral Glucose Insulin Sensitivity
|
Immediately following high fat diet intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Metabolic Flexibility (Respiratory Exchange Ratio) via Indirect Calorimetry
Tidsramme: Immediately following high fat diet intervention
|
Respiratory Exchange Ratio, Glucose Oxidation, Fatty Acid Oxidation
|
Immediately following high fat diet intervention
|
|
Carotid Femoral Pulse Wave velocity
Tidsramme: Immediately following high fat diet intervention
|
Carotid Femoral Pulse Wave Velcoity
|
Immediately following high fat diet intervention
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Matthew Barberio, George Washington University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
10. februar 2025
Primær fullføring (Faktiske)
7. april 2026
Studiet fullført (Faktiske)
9. april 2026
Datoer for studieregistrering
Først innsendt
11. mai 2026
Først innsendt som oppfylte QC-kriteriene
4. juni 2026
Først lagt ut (Faktiske)
8. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
8. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
4. juni 2026
Sist bekreftet
1. april 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NCR246197
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Individual data will be annonymized by study ID number and removed of any identifying information.
Data will be shared upon reasonable request.
IPD-delingstidsramme
Upon publication, data will be shared upon reasonable request to the corresponding author.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .